GENE ONLINE|News &
Opinion
Blog

2021-08-10| China

China Allows Trials to Evaluate Mixing and Matching of INOVIO, Sinovac Vaccines

by Tyler Chen
Share To

To quickly vaccinate the global population, several biotech companies have launched clinical trials to examine the efficacy and safety of mixing COVID-19 vaccines. So, a second shot of the same vaccine wouldn’t be necessary for the vaccination to remain effective.

 

Mixing a DNA and an Inactivated Vaccine

On August 9th, China allowed Inovio to conduct two clinical trials mixing its DNA vaccine, INO-4800, and the WHO-approved inactivated vaccine, Sinovac’s CoronaVac. The trials will investigate the safety, tolerability, and immunogenicity of the combination.

In fact, the mixing of INO-4800 and CoronaVac have already been examined in animal models. Results show increased levels of antigen-specific binding antibodies, neutralizing antibodies by both live-virus neutralization assay and hACE2 receptor blocking assay, and antigen-specific T cell immune responses.

 

INO-4800’s Clinical Progress

Currently, INO-4800 has entered the Phase 3 segment of the Phase 2/3 INNOVATE trial. The global trial will take place in countries in Latin America, Asia, and Africa. According to Phase 1 and 2 trials, INO-4800 could generate a strong CD8 T cell level against the Delta variant and induce balanced T cells and B cells immune response.

The strongest suit of INO-4800 lies in its ability to be stable at room temperature for over 1 year and at 37°C for 1 week, alleviating the cold chain requirements in transportation. Together with the anti-Delta variant activity, INO-4800 could be the primary and booster dose and able to reach every corner of the world, conducting vaccination in tougher conditions.

 

Mixing of Pfizer and AZ Vaccines

As for other such studies, the mixing of AstraZeneca vaccine (ChAdOx1-S, Vaxzevria) and Pfizer vaccine (BNT162b2, Comirnaty) are proven to increase neutralizing antibodies substantially compared to taking 2 doses of ChAdOx1-S. And patients only showed mild to moderate levels of adverse events, which is a positive safety profile.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
New Regulatory Measures in China A First in the Fight Against Sedentary Behavior in Children
2024-05-24
R&D
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
LATEST
Wistar and Accelerated Biosciences Partner to Develop Novel hTSCs Platform for Immunotherapies
2024-07-15
Accelerated Bio and Pluristyx Generate Clinical-Grade Induced Pluripotent Stem Cells from Reprogrammed Human Trophoblast Stem Cells
2024-07-12
Novo Nordisk and PT Bio Farma Agree to Enhance Insulin Production for Diabetes Patients in Indonesia
2024-07-12
Alzheimer’s Drug LEQEMBI Approved for Treatment in Hong Kong
2024-07-12
Foreseen Biotech Strikes $1.03B Deal with Ipsen for First-in-Class ADC
2024-07-12
Synthetic Biology’s Innovator Dr. John Cumbers – Addressing Inefficiencies in Biopharma and Economic Sustainability
2024-07-11
Delivering Affordable Biologic Medicines Worldwide: An Interview with Tanvex Chairman and CEO, Henry Chen
2024-07-11
EVENT
Scroll to Top